TY - JOUR
T1 - Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma
T2 - An INRG Project
AU - Sokol, Elizabeth
AU - Desai, Ami V.
AU - Applebaum, Mark A.
AU - Valteau-Couanet, Dominique
AU - Park, Julie R.
AU - Pearson, Andrew D.J.
AU - Schleiermacher, Gudrun
AU - Irwin, Meredith S.
AU - Hogarty, Michael
AU - Naranjo, Arlene
AU - Volchenboum, Samuel
AU - Cohn, Susan L.
AU - London, Wendy B.
N1 - Funding Information:
The International Neuroblastoma Risk Group Data Commons is supported in part by the William Guy Forbeck Research Foundation, the St. Baldrick’s Foundation, the Little Heroes Cancer Research Fund, the Children’s Neuroblastoma Cancer Foundation, the Neuroblastoma Children’s Cancer Foundation, the Super Jake Foundation, the Matthew Bittker Foundation, the Alex’s Lemonade Stand Foundation, the Rally Foundation for Childhood Cancer Research, and the Bear Necessities Pediatric Research Foundation. Data included in the International Neuroblastoma Risk Group Data Commons were provided by the Children’s Oncology Group, the Pediatric Oncology Group, the Children’s Cancer Study Group, the German Gesellschaft für Pädiatrische Onkologie und Hämatologie, the European Neuroblastoma Study Group, the International Society of Paediatric Oncology Europe Neuroblastoma Group, the Japanese Neuroblastoma Study Group, the Japanese Infantile Neuroblastoma Co-operative Study Group, the Spanish Neuroblastoma Group, and the Italian Neuroblastoma Group.
Publisher Copyright:
© 2020 by American Society of Clinical Oncology.
PY - 2020
Y1 - 2020
N2 - PURPOSE The Children’s Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked International Neuroblastoma Pathology Classification (INPC) criteria. By definition, this leads to a duplication of the prognostic contribution of age. The individual histologic features underlying the INPC have prognostic strength and are incorporated in the International Neuroblastoma Risk Group classification schema. Here, we analyzed data in the International Neuroblastoma Risk Group Data Commons to validate the prognostic strength of the underlying INPC criteria and to determine whether a risk classification devoid of the confounding of age and INPC criteria will identify new prognostic subgroups. PATIENTS AND METHODS Event-free survival of patients diagnosed between 1990 and 2002 (cohort 1; n 5 10,104) and between 2003 and 2016 (cohort 2; n 5 8,761) was analyzed. Recursive partitioning with univariate Cox models of event-free survival (“survival tree regression”) was performed using (1) individual INPC criteria (age at diagnosis, histologic category, mitosis-karyorrhexis index (MKI), grade of differentiation) and (2) factors in (1) plus other COG-risk biomarkers (International Neuroblastoma Staging System [INSS] stage, MYCN status, ploidy). RESULTS The independent prognostic ability of age, histologic category, MKI, and grade were validated. Four histologic prognostic groups were identified (, 18 months with low v high MKI, and $ 18 months with differentiating v undifferentiated/poorly differentiating tumors). Compared with survival trees generated with established COG risk criteria, an additional prognostic subgroup was identified and validated when individual histologic features were analyzed in lieu of INPC. CONCLUSION Replacing INPC with individual histologic features in the COG risk classification will eliminate confounding, facilitate international harmonization of risk classification, and provide a schema for more precise prognostication and refined therapeutic approaches.
AB - PURPOSE The Children’s Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked International Neuroblastoma Pathology Classification (INPC) criteria. By definition, this leads to a duplication of the prognostic contribution of age. The individual histologic features underlying the INPC have prognostic strength and are incorporated in the International Neuroblastoma Risk Group classification schema. Here, we analyzed data in the International Neuroblastoma Risk Group Data Commons to validate the prognostic strength of the underlying INPC criteria and to determine whether a risk classification devoid of the confounding of age and INPC criteria will identify new prognostic subgroups. PATIENTS AND METHODS Event-free survival of patients diagnosed between 1990 and 2002 (cohort 1; n 5 10,104) and between 2003 and 2016 (cohort 2; n 5 8,761) was analyzed. Recursive partitioning with univariate Cox models of event-free survival (“survival tree regression”) was performed using (1) individual INPC criteria (age at diagnosis, histologic category, mitosis-karyorrhexis index (MKI), grade of differentiation) and (2) factors in (1) plus other COG-risk biomarkers (International Neuroblastoma Staging System [INSS] stage, MYCN status, ploidy). RESULTS The independent prognostic ability of age, histologic category, MKI, and grade were validated. Four histologic prognostic groups were identified (, 18 months with low v high MKI, and $ 18 months with differentiating v undifferentiated/poorly differentiating tumors). Compared with survival trees generated with established COG risk criteria, an additional prognostic subgroup was identified and validated when individual histologic features were analyzed in lieu of INPC. CONCLUSION Replacing INPC with individual histologic features in the COG risk classification will eliminate confounding, facilitate international harmonization of risk classification, and provide a schema for more precise prognostication and refined therapeutic approaches.
UR - http://www.scopus.com/inward/record.url?scp=85086052746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086052746&partnerID=8YFLogxK
U2 - 10.1200/JCO.19.03285
DO - 10.1200/JCO.19.03285
M3 - Article
C2 - 32315273
AN - SCOPUS:85086052746
SN - 0732-183X
VL - 38
SP - 1906
EP - 1918
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 17
ER -